• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Biogen, Eisai shares down after critics voice concerns over Alzheimers drug study

July 26, 2018 By Fink Densford

Eisai, Biogen

Biogen (NSDQ:BIIB) and Eisai yesterday released six months of detailed results from a clinical study of its BAN2401 experimental drug for treating Alzheimers, but criticisms quickly emerged casting doubt on the results and sending shares in both companies down.

Researchers working with Eisai and Biogen released trial results showing that high doses of the drug resulted in a statistically significant 30% reduction in the rate of decline when compared to the control group at 18 months, as defined by a custom set of measurements developed by the team.

Investigators also noted a 47% reduction in the rate of decline at 18 months as defined by a standard Alzheimer’s Disease Assessment Scale-cognitive subscale, or ADAS-Cog, according to a Biogen press release.

But critics, skeptical of the results, began to pick through the data and saw what they claimed as possible flaws with the design, according to an Endpoints report.

During a call with Biogen execs, questions arose about the decision by European regulators to move APOe4 carriers out of the high dose arm of the study due to a threat of brain swelling, which they are prone to, while keeping the same individuals in the control group, according to the report.

Carriers of APOe4 are at higher risk of the disease, and often experience a faster progression, according to the report. Critics suggested that moving them out of the high-dose arm, but keeping them in the control group, may have been done to help the high dose arm hit statistical significance, Endpoints reports.

Biogen chief medical officer Al Sandrock did not exclude the possibility that the move may have affected the results, and suggested that a subgroup analysis would be performed to examine the possibility, according to the report.

Shares in Biogen have fallen 9.5% so far today, at $347.42 a while shares of Esai have dropped 9.3%, at $91.75 as of 11:52 a.m. EDT.

Earlier this month, reports emerged that Biogen head Michel Vounatsos is considering entering the medical device market as a possible opportunity to differentiate the pharmaceutical player.

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals Tagged With: Biogen, eisai

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS